BR112013018298A2 - compostos para a redução da produção de beta-amiloides - Google Patents

compostos para a redução da produção de beta-amiloides

Info

Publication number
BR112013018298A2
BR112013018298A2 BR112013018298A BR112013018298A BR112013018298A2 BR 112013018298 A2 BR112013018298 A2 BR 112013018298A2 BR 112013018298 A BR112013018298 A BR 112013018298A BR 112013018298 A BR112013018298 A BR 112013018298A BR 112013018298 A2 BR112013018298 A2 BR 112013018298A2
Authority
BR
Brazil
Prior art keywords
compounds
reducing beta
amyloid
amyloid production
production
Prior art date
Application number
BR112013018298A
Other languages
English (en)
Portuguese (pt)
Inventor
Dmitry S Zuev
Jason M Guernon
Jianliang Shi
John E Macor
Kenneth M Boy
Li Xu
Lorin A Thompson Iii
Richard E Olson
Yong-Jin Wu
Yunhui Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112013018298A2 publication Critical patent/BR112013018298A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013018298A 2011-01-28 2012-01-26 compostos para a redução da produção de beta-amiloides BR112013018298A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437279P 2011-01-28 2011-01-28
PCT/US2012/022665 WO2012103297A1 (en) 2011-01-28 2012-01-26 COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

Publications (1)

Publication Number Publication Date
BR112013018298A2 true BR112013018298A2 (pt) 2016-11-16

Family

ID=45688981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018298A BR112013018298A2 (pt) 2011-01-28 2012-01-26 compostos para a redução da produção de beta-amiloides

Country Status (15)

Country Link
US (1) US8710061B2 (https=)
EP (1) EP2668168B1 (https=)
JP (1) JP5908499B2 (https=)
KR (1) KR20140014152A (https=)
CN (1) CN103328451B (https=)
AR (1) AR084944A1 (https=)
AU (1) AU2012211301B2 (https=)
BR (1) BR112013018298A2 (https=)
CA (1) CA2825906A1 (https=)
EA (1) EA201391097A1 (https=)
IL (1) IL226677A (https=)
MX (1) MX2013008699A (https=)
SG (1) SG191840A1 (https=)
TW (1) TW201309655A (https=)
WO (1) WO2012103297A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025686B1 (pt) 2013-04-15 2020-10-27 Fmc Corporation composto, composições fungicidas e método para o controle das doenças dos vegetais
JP6688503B2 (ja) * 2014-11-21 2020-04-28 大学共同利用機関法人自然科学研究機構 医薬用組成物
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN105017046A (zh) * 2015-07-15 2015-11-04 上海博康精细化工有限公司 一种4-环丙胺基丁酸乙酯的制备方法
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
JP7335242B2 (ja) * 2017-11-27 2023-08-29 エフ. ホフマン-ラ ロシュ アーゲー ピリミジン誘導体
PH12021551635A1 (en) 2019-01-29 2022-05-02 Shandong Xuanzhu Pharma Co Ltd Hexone glucokinase inhibitor and use thereof
CN112028839B (zh) * 2020-09-30 2022-04-12 中国海洋大学 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法
TW202317528A (zh) * 2021-06-24 2023-05-01 美商富曼西公司 用於防治無脊椎有害生物的唑類化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1318997T1 (sl) * 2000-09-15 2006-12-31 Vertex Pharma Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
TW201030002A (en) * 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
US8637525B2 (en) * 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物

Also Published As

Publication number Publication date
JP5908499B2 (ja) 2016-04-26
JP2014503590A (ja) 2014-02-13
AU2012211301B2 (en) 2016-02-25
US20130030011A1 (en) 2013-01-31
EP2668168B1 (en) 2017-03-01
CN103328451A (zh) 2013-09-25
WO2012103297A1 (en) 2012-08-02
AR084944A1 (es) 2013-07-10
AU2012211301A1 (en) 2013-09-19
SG191840A1 (en) 2013-08-30
KR20140014152A (ko) 2014-02-05
CN103328451B (zh) 2015-06-10
EP2668168A1 (en) 2013-12-04
US8710061B2 (en) 2014-04-29
MX2013008699A (es) 2013-08-21
EA201391097A1 (ru) 2013-11-29
TW201309655A (zh) 2013-03-01
CA2825906A1 (en) 2012-08-02
IL226677A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
BR112013018298A2 (pt) compostos para a redução da produção de beta-amiloides
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112015014253A2 (pt) produtos de higiene bucal que compreendem um complexo de haleto de aminoácido e zinco tetrabásico
CY1120805T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
BRPI0908421B8 (pt) solução estável de um composto farmacêutico
MX369388B (es) Moduladores heterociclicos de sintesis lipidica.
PH12012501390A1 (en) Fatty acid fumarate derivatives and their uses
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
BR112013020513A2 (pt) adoçante stevia altamente solúvel
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201201661A1 (ru) Новые аминопиразолохиназолины
EA201690520A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
NI201400022A (es) Composición farmacéutica que comprende un ciclopolisacárido
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
MX340928B (es) Derivados de oxazolina e isoxazolina como moduladores de canales de calcio de liberación activa (crac).
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
SG10201900541QA (en) Derivatives of xanthone compounds
BR112014008401A2 (pt) processo para a preparação de metoxi melonal
GEP20146183B (en) Process for preparation of l-arginine salt of perindopril
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.